SCHEMBL22280528

SCHEMBL22280528

CC(C)(C)OC(=O)N1CC[C@H](c2nc(-c3ccc(I)cc3)no2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 4/20 0.53
HDAC6 Q9UBN7 2/20 0.53
GPR119 Q8TDV5 2/20 0.52
GRM5 P41594 1/20 0.50
CLPP Q16740 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
ALDH1A1 P00352 2/20 0.49
MAPT P10636 1/20 0.49
HSD11B1 P28845 4/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
FAAH O00519 1/20 0.48
MGLL Q99685 1/20 0.48
LMNA P02545 1/20 0.48
TSHR P16473 1/20 0.48
KDM4E B2RXH2 1/20 0.47
GAA P10253 1/20 0.47
CYP1A2 P05177 1/20 0.47
POLB P06746 1/20 0.47
CYP3A4 P08684 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4414338 0.94 GPR119 (0.56) HDAC4HDAC6GPR119SMN1; SMN2ALDH1A1
SCHEMBL22265697 0.92 FAAH (0.54) HDAC4HDAC6GPR119GRM5CLPP
SCHEMBL22280590 0.91 LMNA (0.57) HDAC4HDAC6GPR119GRM5CLPP
SCHEMBL22280276 0.91 LMNA (0.57) HDAC4HDAC6GPR119GRM5CLPP
SCHEMBL22280637 0.90 HDAC4 (0.55) HDAC4HDAC6GPR119GRM5CLPP
SCHEMBL22280496 0.88 HDAC4 (0.51) HDAC4HDAC6GPR119GRM5CLPP
SCHEMBL22280326 0.87 HDAC4 (0.60) HDAC4HDAC6GPR119GRM5CLPP
SCHEMBL29523281 0.86 HDAC4 (0.52) HDAC4HDAC6GPR119GRM5CLPP
SCHEMBL22280436 0.86 ALDH1A1 (0.64) HDAC4HDAC6GRM5CLPPSMN1; SMN2
SCHEMBL192613 0.86 ALDH1A1 (0.64) HDAC4HDAC6GRM5CLPPSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590083-B2 Inhibitors of spinster homolog 2 (SPNS2) for use in therapy UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2026-03-31 US disclosed
US-20220089581-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-03-24 US disclosed
WO-2020154431-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY LYNCH KEVIN R (US) 2020-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089581-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY SPNS2, SPCS2, SMN1; SMN2 HDAC4 2770/4885HDAC6 646/4885GPR119 2305/4885
US-12590083-B2 Inhibitors of spinster homolog 2 (SPNS2) for use in therapy SPNS2, SLC20A2, S1PR2 HDAC4 3573/4885HDAC6 3568/4885GPR119 627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.